Webinars, Pharmaceutical

Nose to Brain Drug Delivery – A Promising Future

Nose to brain drug delivery has considerable potential to address currently unmet needs for CNS therapeutics for the treatment of disorders such as Alzheimer’s, Parkinson’s, and multiple sclerosis.

This webinar discusses the mechanisms of drug delivery to the CNS, drug delivery technology considerations, and formulation ingredients and strategies, including an examination of the pros and cons of liquid vs. powder formulation. By bypassing the blood brain barrier, nose to brain drug delivery offers potential to deliver different drugs and lower doses with minimal systemic effect. The criticality of successful targeting of the olfactory region is noted and the beneficial role of excipients such as mucoadhesives and penetration enhancers is outlined.

Aptar Pharma’s expertise in all aspects of the development and reformulation of drugs for nose to brain delivery is highlighted.

Watch the webinar
Speaker(s): Reenal Gandhi Gemma Budd
22 Apr 2022

Learn more about Aptar Pharma Expertise
in Nasal Drug Delivery

Find Out More

This Might Also Be of Interest

21 Jun 2022

Nasal Drug Delivery Challenges and Trends Ahead

Publications, Pharmaceutical, Device Innovations, Brand Differentiation, Market Insights, Product Solutions

Read More
9 Jun 2022

Aptar Pharma discusses digital therapeutics for chronic conditions

Publications, Pharmaceutical, Device Innovations, Brand Differentiation, Market Insights, Product Solutions

Read More
16 May 2022

Healthcare Packaging: The Future of Medical Devices

Publications, Pharmaceutical, Device Innovations, Brand Differentiation, Market Insights, Product Solutions

Read More
25 Apr 2022

Nasal Drug Development, Trends and Challenges with Nasal Formulations

Publications, Pharmaceutical, Device Innovations, Brand Differentiation, Market Insights, Product Solutions

Read More
1 10 11 12 13 14 25

Request Access

Close

Requesting access to Nose to Brain Drug Delivery – A Promising Future.

  • This field is for validation purposes and should be left unchanged.
Back To Top